论文部分内容阅读
目的:探讨硫酸镁与酚妥拉明联合川芎嗪注射液对妊娠期高血压综合征(PIH)患者血压的控制及其对母婴结局的影响。方法:选取2014年2月—2016年8月收治的PIH患者96例,根据治疗方案的不同将其分为对照组和观察组,每组48例;对照组患者给予硫酸镁与酚妥拉明治疗,观察组患者在对照组基础上加用川芎嗪注射液治疗,比较两组患者治疗12 d后血压控制的总有效率和对母婴结局情况。结果:治疗前两组患者收缩压(SBP)和舒张压(DBP)测得值经比较其差异无统计学意义(P>0.05);观察组患者治疗后SBP、DBP均低于对照组(P<0.05),治疗后的总有效率为93.75%高于对照组为77.08%(P<0.05);观察组患者不良母婴结局的总发生率为8.33%低于对照组为39.58%(P<0.05)。结论:采用硫酸镁与酚妥拉明联合川芎嗪注射液治疗PIH患者,其降压的疗效较为显著,并改善了不良母婴结局。
Objective: To investigate the effect of magnesium sulfate and phentolamine combined with ligustrazine on blood pressure in patients with gestational hypertension (PIH) and its effect on maternal and infant outcomes. Methods: A total of 96 PIH patients were selected from February 2014 to August 2016. According to the different treatment regimens, they were divided into control group and observation group, 48 cases in each group. Patients in the control group were given magnesium sulfate and phentolamine The patients in the treatment group and the observation group were treated with ligustrazine injection on the basis of the control group. The total effective rate of blood pressure control and maternal and infant outcomes were compared between the two groups after 12 days of treatment. Results: There was no significant difference in SBP and DBP between the two groups before treatment (P> 0.05). The SBP and DBP in the observation group were lower than those in the control group (P <0.05). The total effective rate after treatment was 93.75%, which was significantly higher than that of the control group (77.08%, P <0.05). The overall incidence of adverse maternal-infant outcome was 8.33% in the observation group and 39.58% in the control group (P < 0.05). CONCLUSIONS: The use of magnesium sulfate and phentolamine combined with ligustrazine in the treatment of PIH patients, the antihypertensive effect is more significant and to improve the adverse maternal and infant outcomes.